Recursion Pharmaceuticals, Inc. RXRX Gain on sale of business and assets
Gain on sale of business and assets at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfBusiness.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s gain on sale of business and assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s gain on sale of business and assets?
- Recursion Pharmaceuticals, Inc. (RXRX) reported gain on sale of business and assets of $0 in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s gain on sale of business and assets changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s gain on sale of business and assets increased by 100.0% year-over-year, from -$4.5M to $0.